Format

Send to

Choose Destination
J Psychopharmacol. 2017 Apr;31(4):434-441. doi: 10.1177/0269881117691590. Epub 2017 Feb 15.

First in human trial of a type I positive allosteric modulator of alpha7-nicotinic acetylcholine receptors: Pharmacokinetics, safety, and evidence for neurocognitive effect of AVL-3288.

Author information

1
1 Department of Pharmacology, School of Medicine, University of California Irvine, Irvine, USA.
2
2 Department of Psychiatry, University of Colorado School of Medicine, Aurora, USA.
3
3 Anvyl LLC, 18092 Sky Park South, Suite F, Irvine, USA.
4
4 Division of Cardiology, Department of Medicine, University of Colorado School of Medicine, Aurora, USA.

Abstract

Type I positive allosteric modulators (PAMs) of the alpha7-nicotinic receptor enhance its cholinergic activation while preserving the spatiotemporal features of synaptic transmission and the receptor's characteristic rapid desensitization kinetics. Alpha7-nicotinic receptor agonists have shown promise for improving cognition in schizophrenia, but longer-term trials have been disappointing. Therefore, the type I PAM AVL-3288 was evaluated for safety and preliminary evidence of neurocognitive effect in healthy human subjects. Single-dose oral administration in ascending doses was conducted in a double-blind, placebo-controlled Phase I trial in non-smokers. The trial found indication of positive but non-significant effects on neurocognition at 10 and 30 mg, two doses that produced overlapping peak levels. There was also some evidence for effects on inhibition of the P50 auditory evoked potential to repeated stimuli, a biomarker that responds to alpha7-nicotinic receptor activation. The pharmacokinetic characteristics were consistent between subjects, and there were no safety concerns. The effects and safety profile were also assessed at 3 mg in a cohort of smokers, in whom concurrent nicotine administration did not alter either effects or safety. The trial demonstrates that a type I PAM can be safely administered to humans and that it has potential positive neurocognitive effects in central nervous system (CNS) disorders.

KEYWORDS:

Receptors; allosteric modulators; cognition; drug evaluation; nicotinic; schizophrenia

PMID:
28196430
DOI:
10.1177/0269881117691590
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center